CIB2

Across TCGA pan-cancer cohorts, CIB2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CIB2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CIB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIB2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

STAD, SKCM, and UCEC are the cancer types where CIB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.660	.009	15	view →
SKCM	DFS	Median	All	1.000	0.602	.029	5	view →
UCEC	DFS	Median	All	1.000	0.892	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CIB2–STAD (OS)

Open the STAD breakdown →